Myriad Genetics, Inc. (MYGN) Company Profile & Statistics

Myriad Genetics, Inc.
MYGN
(Nasdaq - US)
N/A
17.98
-0.65 (-3.49%)
in:usd•As of: Apr 25, 2024 15:59 UTC -4
Open
18.03
High
18.21
Low
17.92

About Myriad Genetics, Inc.

CEO

Paul J. Diaz

Headquarters

322 north 2200 west

salt lake city, ut 84116, united states

Auditor

Ernst & Young LLP

Employees

2,700

Share Holders

Website

www.myriad.com

Industry

medical specialties

Sector

health technology

Company Overview

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made significant progress in transition & expand the hereditary cancer market, diversify revenues by commercializing its new products, increase the company's international contribution by investing in large countries, gaining reimbursement for new products, increasing international RNA kit revenue and enhancing profitability. Its flagship product BRACAnalysis offers a comprehensive analysis of BRCA1 and BRCA2 genes to assess a woman's risk of hereditary breast and ovarian cancers. Its major products are myRisk Hereditary Cancer, myPlan Lung Cancer and molecular diagnostic test myPath Melanoma. It acquired Counsyl, Inc. The company has 2 operating units: Molecular diagnostic & Pharmaceutical and clinical services.

Myriad Genetics, Inc. Statistics

Valuation Measures

Market Capitalization ²	1.63B
Enterprise Value	1.53B
Enterprise Value/EBITDA (ttm)	-7.84
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.95
Price to Sales (ttm)	2.23
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	68.62%
Operating Margin (ttm)	-8.10%
Profit Margin (ttm)	-35.32%
Return on Equity (ttm)	-8.03%
Return on Invested Capital (ttm)	-33.85%
Return on Assets (ttm)	-5.24%

Income Statement

Revenue (ttm)	753.20M
Revenue Per Share (ttm)	8.38
Gross Profit (ttm)	517.00M
EBITDA (ttm)³	-195.50M
Net Income Avi to Common (ttm)	-263.30M
Diluted EPS (ttm)	-3.20

Share Statistics

Beta (5Y Monthly)	1.95
52-Week Change	-14.30%
S&P500 52-Week Change	24.47%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	89.87M
Dividend Yield	0.00%
Float ⁴	88.67M
% Held by Insiders	2.00%
% Held by Institutions	99.02%

Balance Sheet

Total Cash (mrq)	140.90M
Total Cash Per Share (mrq)	1.57
Total Debt (mrq)	38.50M
Total Debt/Equity (mrq)	4.92%
Current Ratio (mrq)	2.01%
Quick Ratio (mrq)	1.87%
Book Value Per Share (mrq)	8.71

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.34
Free Cash Flow (ytd)	-174.10M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Myriad Genetics, Inc.

Trade With A Regulated Broker